Targeting the tumor immune microenvironment could become a potential therapeutic modality for aggressive pituitary adenoma
Authors:
Preprint
- 12 August 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Purpose This study aimed to explore the relationship between the aggressiveness and immune cell infiltration in pituitary adenoma (PA) and provide the basis for immuno-targeting therapies. Methods One hundred three patients with PA who underwent surgery at a single institution were retrospectively identified. The infiltration of macrophages and T-lymphocytes was quantitatively assessed. Results The number of CD68 + macrophages was positively correlated with Knosp (P = 0.003) and MMP-9 expression grades (P = 0.00). The infiltration of CD163 + macrophages differed among Knosp (P = 0.022) and MMP-9 grades (P = 0.04). CD8 + tumor-infiltrating lymphocytes (TILs) were also positively associated with Knosp (P = 0.002) and MMP-9 grades (P = 0.01). Interestingly, MGMT expression was positively correlated with MMP-9 staining extent (P = 0.000). The quantities of CD8 + TILs (P = 0.016), CD68 + macrophages (P = 0.000), and CD163 + macrophages (P = 0.043) were negatively associated with MGMT expression levels. The number of CD68 + macrophages in the PD-L1 negative group was significantly more than that in the PD-L1 positive group (P = 0.01). The rate of PD-L1 positivity was positively correlated with the Ki-67 index (P = 0.046) and p53 expression (P = 0.029). Conclusion Targeted therapy for macrophages and CD8 + TILs could be a helpful treatment in the future for aggressive PA. Temozolomide (TMZ) may have better effects on the treatment of PAs with greater immune cell infiltration. Anti-PD-L1 therapy may better respond to PAs with higher Ki-67 and p53 expression and more infiltrating CD68 + macrophages. Multiple treatment modalities, especially combined immunotherapy, or combination immunotherapy with TMZ, could become a novel therapeutic strategy for aggressive PA.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- MGMT expression and pituitary tumours: relationship to tumour biologyPituitary, 2012
- Balancing repair and tolerance of DNA damage caused by alkylating agentsNature Reviews Cancer, 2012
- Endogenous Matrix Metalloproteinases 2 and 9 Regulate Activation of CD4+ and CD8+ T cellsAmerican Journal of Respiratory Cell and Molecular Biology, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumoursClinical Endocrinology, 2009
- MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapyActa Neuropathologica, 2007
- Matrix metalloproteinase-9, a potential biological marker in invasive pituitary adenomasPituitary, 2007
- Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastatVirchows Archiv, 2007
- Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokinesThe FASEB Journal, 2004
- Pathology of invasive pituitary tumors with special reference to functional classificationJournal of Neurosurgery, 1986